Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Young's cites warm weather as it hails solid Q1 performance

(Sharecast News) - Pub group Young's hailed a solid first-quarter performance on Wednesday as the strong trading momentum reported in its full-year results in June has continued. In an update ahead of its annual meeting, the company said revenue in the first 14 weeks of the financial year beginning 1 April rose 6.6% in total and 7.0% on a like-for-like basis versus last year.

Young's it benefitted from long periods of warm and sunny weather in spring and early summer, supporting growth particularly in its gardens and riverside pubs.

"These results are even more pleasing when measured against the prior year comparator, which benefitted from the significant positive impact of EURO24 Championship on performance in June and early July," the company said.

Young's expressed confidence about the year ahead "despite the well-publicised challenges" faced by the industry.

The group said it continues to invest in its estate, having already completed several schemes to take advantage of the summer trading period.

Chief executive Simon Dodd said: "We are delighted to be reporting excellent trading over the first quarter of the new financial year, particularly against such a strong comparator.

"Young's pubs are thriving, and our strategy of employing the very best teams, and maintaining a premium, well-invested and differentiated estate, continues to deliver industry leading results. Our business is performing well, and we are confident about the year ahead."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.